The pathogenic role of protein aggregation in inflammatory demyelination

蛋白质聚集在炎症脱髓鞘中的致病作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Our long-term goal is to define and characterize the mechanisms underlying tissue injury in multiple sclerosis (MS), the most common demyelinating disease of the central nervous system in humans. In recent years, oxidative stress has been implicated in the pathophysiology of both MS and its animal model, experimental autoimmune encephalomyelitis (EAE). Previous studies from our laboratory have shown that MS and EAE, like several other neurological disorders, are characterized by the accumulation of carbonylated (oxidized) proteins within CNS cells. We have also demonstrated that the build-up of oxidized and other misfolded proteins in these disorders is a consequence of decreased activity of the proteasome, the proteolytic machinery responsible for their removal. Carbonylation and other oxidative protein modifications are known to cause inappropriate inter- and intra-protein cross-links as well as protein misfolding. This, in turn, results in the formation of protein aggregates that we believe contribute to the demise of neural cells and ultimately tissue damage. Indeed, we have obtained preliminary evidence that aggregates containing oxidized proteins accumulate in the CNS of MS patients and EAE mice and that inhibition of protein aggregation prevents neuronal cell death in culture. Based on these novel findings, we hypothesize that protein aggregation plays a pathogenic role in EAE. To test this idea, we will (1) quantify the temporal/spatial pattern of protein aggregation and its relationship to the extent of neuronal and oligodendroglial cell death in the spinal cord during the course of MOG peptide-induced EAE, and (2) examine the prophylactic and therapeutic efficacy of two chemically- distinct protein aggregation inhibitors at preventing cell death and tissue injury and at reducing neurological symptoms of EAE. If successful, these studies will not only demonstrate that protein aggregation is pathogenic in inflammatory demyelinating disease but also will provide the basis for developing new or testing previously identified non-toxic aggregation inhibitors for an improved clinical management of MS.
描述(由申请人提供):我们的长期目标是定义和表征多发性硬化症(MS)组织损伤的机制,MS是人类中枢神经系统最常见的脱髓鞘疾病。近年来,氧化应激已被牵连在MS及其动物模型,实验性自身免疫性脑脊髓炎(EAE)的病理生理学。我们实验室以前的研究表明,MS和EAE与其他几种神经系统疾病一样,其特征在于CNS细胞内羰基化(氧化)蛋白质的积累。我们还证明,在这些疾病中氧化和其他错误折叠的蛋白质的积累是蛋白酶体活性降低的结果,蛋白酶体是负责去除它们的蛋白水解机制。已知羰基化和其他氧化蛋白质修饰会导致蛋白质间和蛋白质内不适当的交联以及蛋白质错误折叠。这反过来又导致蛋白质聚集体的形成,我们认为这有助于神经细胞的死亡和最终的组织损伤。事实上,我们已经获得了初步的证据,含有氧化蛋白质的聚集体积累在MS患者和EAE小鼠的CNS中,并且抑制蛋白质聚集可以防止培养中的神经元细胞死亡。基于这些新的发现,我们假设蛋白质聚集在EAE中起致病作用。为了测试这个想法,我们将(1)量化蛋白质聚集的时间/空间模式及其与MOG肽诱导的EAE过程中脊髓中神经元和少突胶质细胞死亡程度的关系,和(2)检查两种化学上不同的蛋白质聚集抑制剂在预防细胞死亡和组织损伤以及在减少EAE的神经症状方面的预防和治疗功效。如果成功,这些研究将不仅证明蛋白质聚集在炎性脱髓鞘疾病中是致病性的,而且还将为开发新的或测试先前确定的无毒聚集抑制剂以改善MS的临床管理提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OSCAR A BIZZOZERO其他文献

OSCAR A BIZZOZERO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OSCAR A BIZZOZERO', 18)}}的其他基金

Cellular, molecular and functional characterization of proteasomes in EAE
EAE 中蛋白酶体的细胞、分子和功能表征
  • 批准号:
    8723318
  • 财政年份:
    2013
  • 资助金额:
    $ 18.69万
  • 项目类别:
Cellular, molecular and functional characterization of proteasomes in EAE
EAE 中蛋白酶体的细胞、分子和功能表征
  • 批准号:
    8636605
  • 财政年份:
    2013
  • 资助金额:
    $ 18.69万
  • 项目类别:
The pathogenic role of protein aggregation in inflammatory demyelination
蛋白质聚集在炎症脱髓鞘中的致病作用
  • 批准号:
    8564373
  • 财政年份:
    2013
  • 资助金额:
    $ 18.69万
  • 项目类别:
PROTEIN CARBONYLATION AND AXONAL DAMAGE IN EAE
EAE 中的蛋白质羧化和轴突损伤
  • 批准号:
    7463475
  • 财政年份:
    2008
  • 资助金额:
    $ 18.69万
  • 项目类别:
PROTEIN CARBONYLATION AND AXONAL DAMAGE IN EAE
EAE 中的蛋白质羧化和轴突损伤
  • 批准号:
    7591137
  • 财政年份:
    2008
  • 资助金额:
    $ 18.69万
  • 项目类别:
PROTEIN CARBONYLATION AND AXONAL DAMAGE IN EAE
EAE 中的蛋白质羧化和轴突损伤
  • 批准号:
    8044003
  • 财政年份:
    2008
  • 资助金额:
    $ 18.69万
  • 项目类别:
PROTEIN CARBONYLATION AND AXONAL DAMAGE IN EAE
EAE 中的蛋白质羧化和轴突损伤
  • 批准号:
    7795735
  • 财政年份:
    2008
  • 资助金额:
    $ 18.69万
  • 项目类别:
PROTEIN CARBONYLATION AND AXONAL DAMAGE IN EAE
EAE 中的蛋白质羧化和轴突损伤
  • 批准号:
    8242025
  • 财政年份:
    2008
  • 资助金额:
    $ 18.69万
  • 项目类别:
MECHANISMS OF NO-MEDIATED PROTEIN S-NITROSYLATION IN EAE
EAE 中无介导蛋白质 S-亚硝基化机制
  • 批准号:
    6709773
  • 财政年份:
    2004
  • 资助金额:
    $ 18.69万
  • 项目类别:
MECHANISMS OF NO-MEDIATED PROTEIN S-NITROSYLATION IN EAE
EAE 中无介导蛋白质 S-亚硝基化机制
  • 批准号:
    6990479
  • 财政年份:
    2004
  • 资助金额:
    $ 18.69万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 18.69万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了